Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Alzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

Patients who took lecanemab extended their time at home for an additional 10 months, while donanemab enabled them to live independently for eight more months, according to a WashU press release.

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking ...

In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...

M Health Fairview now offers both Alzheimer's infusion treatments — lecanemab and donanemab — both of which slow the ...